A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer

Cancer

Volumn 115, Issue 4, 2009, Pages 776-783

  Heng, Daniel Y C ^a,b,c   Chi, Kim N ^b   Murray, Nevin ^b   Jin, Tao ^c   Garcia, Jorge A ^c   Bukowski, Ronald M ^c   Rini, Brian I ^c   Kollmannsberger, Christian ^a,b  

^a TOM BAKER CANCER CENTRE   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Overall survival; Renal cell carcinoma; Sunitinib; Tyrosine kinase inhibitor; Vascular endothelial growth factor

Indexed keywords

INTERFERON; SUNITINIB;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; INTERFERONS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PYRROLES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 60849120120     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24051     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57:43-66.
2. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005; 23:133-141.
3. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003; 21:3127-3132.
4. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med. 1998; 338:1272-1278.
5. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005; CD001425.
6. Negrier S, Perol D, Ravaud A, et al. Medroxyprogesterone, interferon alfa-2a, interleukin-2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer. 2007; 110:2468-2477.
7. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005; 353:2477-2490.
8. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356:115-124.
9. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356:125-134.
10. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370:2103-2111.
11. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356:2271-2281.
12. Motzer RJ, Escudier B, Oudard S, et al. RAD001 vs. placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter phase III study. J Clin Oncol. 2008; 26S:LBA5026.
13. Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2008; 26S:5024.
14. Landewe R, van der Heijde D. Primer: challenges in randomized and observational studies. Nat Clin Pract Rheu- matol. 2007; 3:661-666.
15. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. JClin Oncol. 2005; 23:5027-5033.
16. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear- cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007; 110:543-550.
17. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. JClinOncol. 2002; 20:289-296.
18. Common Drug Review, Canadian Agency for Drugs and Technologies in Health: CEDAC Final Recommendation on Reconsideration and Reasons for Recommendation- Sunitinib, 2007. Available at: http://cadth.ca/media/cdr/complete/cdr-complete- sutent-e-april-26-2007%20.pdf Accessed on July 7, 2008.
19. Hanlon P: Evidence submitted by Kidney Cancer UK(NICE 90), March 2007 update. Available at: http://www.publications.parliament.uk/pa/cm200607/ cmselect/cmhealth/ 503/503we39.htm Accessed on July 7, 2008.
20. Warren MA, Venner PM, North SA, et al. Then and now: the effect of tyrosine kinase inhibitors on survival in patients with metastatic renal cell carcinoma in Alberta, Canada. JClin Oncol. 2008; 26S:16033.
21. Heng DY, Chi KN, Murray N, et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer (mRCC). Paper presented at: Genitourinary Cancers Symposium; February 14-16, 2008; San Francisco, Calif.
22. Gore ME, Porta S, Oudard S, et al. Sunitinib in meta- static renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol. 2007; 25(18 suppl): 010.
23. Porta C, Szcyzylik C, Bracarda S, et al. Short- and long- term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2008; 26S:5114.
24. Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy gainst advanced renal cell carcinoma. J Urol. 2007; 178:1883-1887.
25. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension ofthe Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated meta- static renal cell carcinoma. J Clin Oncol. 2005; 23:832-841.